PLCSD News Alert Viveve Medical Inc. (PLCSD) 0.8100 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 25, 2014 at 11:45 PM

Viveve Medical Inc. (PLCSD) 0.8100 $PLCSD

Viveve Initiates the VIVEVE I Clinical Trial
Marketwired - Tue Dec 16, 7:28AM CST
Viveve Medical, Inc. ("Viveve"

(OTCQB: VIVMF), a company focused on women's health, today announced that the first patient was successfully treated at the Allan Centre, in Calgary Canada, by Dr. Bruce Allan, a leading Canadian gynecologist. The VIVEVE I clinical study -- VIveve Treatment of the Vaginal Introitus to EValuate Efficacy is a randomized, blinded and sham-controlled trial designed to demonstrate the efficacy of the ViveveÂ® Treatment versus a sham control procedure for the treatment of vaginal introital laxity.

Viveve Presentation Now Available for On-Demand Viewing
CNW Group - Mon Dec 08, 7:29AM CST
Viveve Medical, Inc. (OTC QB: VIVMF) ("Viveve"

, the parent company to Viveve, Inc., a company focused on women's health, today announced that the December 4th presentation, is now available for on-demand viewing at VirtualInvestorConferences.com.

Viveve Announces Presentation at World Meeting in Paris
Marketwired - Wed Dec 03, 9:24AM CST
Viveve Medical, Inc. ("Viveve"

(OTCQB: VIVMF), a company focused on women's health, today announced that Dr. Michael Krychman, a medical advisor to the company, a world renowned specialist in sexual health and the Executive Director of The Southern California Center for Sexual Health and Survivorship, will present the ViveveÂ® System as a non-invasive treatment for vaginal introital laxity to improve sexual function in adult females during the 20th World Congress in Obstetrics, Gynecology & Infertility, being held December 4th through the 7th in Paris.

Viveve to Webcast Live at VirtualInvestorConferences.com
PR Newswire - Mon Nov 24, 7:28AM CST
Company invites individual and institutional investors, as well as advisors to attend this interactive, real-time virtual investor conference

Viveve Announces the Launch of Its New Website
Marketwired - Wed Nov 19, 4:27PM CST
Viveve Medical, Inc. ("Viveve"

(PINKSHEETS: VIVMF), the parent company to Viveve, Inc., a company focused on women's health, today announced that it unveiled its new website www.viveve.com. The site now offers a clean, modern design, easy-to-navigate functionality, and a content-rich experience.

Viveve to Present at the Canaccord Genuity - 2014 Medical Technology & Diagnostics Forum
Marketwired - Tue Nov 18, 11:44PM CST
Viveve Medical, Inc. ("Viveve"

(PINKSHEETS: VIVMF), a company focused on women's health, today announced that Patricia Scheller, Chief Executive Officer, will present at the Canaccord Genuity, 2014 Medical Technology & Diagnostics Forum on Thursday, November 20th at 8:20am EST at the Westin Grand Central in New York, NY.

Viveve Reports Third Quarter 2014 Financial Results
Marketwired - Fri Nov 14, 8:25AM CST
Viveve Medical, Inc. ("Viveve"

(PINKSHEETS: VIVMF), the parent company to Viveve, Inc., a company focused on women's health, today reported financial results for the period ended September 30, 2014. These results are the first financial results reported for Viveve following the merger of Viveve, Inc. with PLC Systems, Inc.

Cepheid Q3 Loss Narrower than Expected, Sales View Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 9:20AM CDT
Cepheid (CPHD) experienced a solid 15.1% year-over-year growth in revenues of $115.2 million in the third quarter.
ATEC: 1.27 (-0.06), CPHD: 53.39 (+0.51), ANGO: 19.19 (+0.33)

Luminex (LMNX) Crumbles: Stock Falls by 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 8:00AM CDT
Luminex has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for last 24 hours
ATEC: 1.27 (-0.06), LMNX: 18.60 (+0.37), ANGO: 19.19 (+0.33)

AngioDynamics Q1 Earnings & Revenues Beat, '15 View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 8:00AM CDT
For fiscal 2015, AngioDynamics Inc. (ANGO) raised its adjusted per share guidance to a range of 65 to 71 cents from the prior expectation of 64 to 70 cents, on the back of stronger than anticipated first-quarter results.
BSX: 13.13 (+0.07), ANGO: 19.19 (+0.33), ERB: 2.81 (-0.04)

Luminex Trends Up, Hits 52-Week High on Strong Q2 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 8:10AM CDT
Shares of Luminex Corporation (LMNX) have been on the rise since it reported impressive 2014 second-quarter results on Jul 28.
ATEC: 1.27 (-0.06), LMNX: 18.60 (+0.37), ERB: 2.81 (-0.04)

Viveve Announces Presentation at World Meeting on Sexual Medicine
Marketwired - Thu Oct 09, 7:28AM CDT
Viveve Medical, Inc. ("Viveve"

(PINKSHEETS: PLCSD), a company focused on women's health, has announced that today Dr. Michael Krychman will present on the Viveve System as a non-invasive treatment for vaginal introital laxity to improve sexual function in adult females during the 16th World Meeting on Sexual Medicine which is taking place in Sao Paulo, Brazil from October 8-12, 2014.

Mazor Robotics Ltd. (MZOR) in Focus: Stock Soars 11.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 8:18AM CDT
Mazor Robotics Ltd. (MZOR) was a big mover last session, as the company saw its shares rise by over 11% on the day.
OPK: 9.63 (+0.21), MZOR: 13.01 (-0.68), ERB: 2.81 (-0.04)

Viveve Announces the Launch of its New Investor Relations Website and Engages Investor Relations Firm
Marketwire - Fri Sep 26, 7:28AM CDT
Viveve Medical, Inc. (PINKSHEETS: PLCSD) (PINKSHEETS: PLCSF) ("Viveve"

, the parent company to Viveve, Inc., a company focused on women's health, unveiled its new Investor Relations website. The site, http://ir.viveve.com, incorporates numerous features to make browsing for investment information a much faster and informative experience for the Company's current and potential investors.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Govee Stirs Halloween Chills with New Sarah Gellar Ad

Lighting Up Halloween the Hollywood Way When it comes to Halloween, folks go nuts driving up the thrill factor at home, and boy, has Govee nailed it this time around. They've dragged Sarah Michelle Gellar into their spooky mix, transforming homes into eerie masterpieces. And let's face it, who better than the 'Buffy the Vampire Slayer' herself to stir those spine-tingling...

Vatrer Power: Lithium Batteries Revolutionize Golf Carts

The humdrum world of golf carts just got a jolt of energy with lithium batteries entering the fray. Vatrer Power, the brain behind some nifty LiFePO4 lithium battery conversions, made some noise at this year's Golf Carting Expo & Dealer Summit in Charleston, South Carolina. Held at the North Charleston Convention Center, this trade show was the industry's premier...

Trading Platforms Poised for Billions by 2031

Forecasts and Fierce Digital Landscapes Just when you thought the online trading realm was getting saturated, the numbers are making it clear: there’s still room for growth—even explosive growth. The online trading platform market is eyeing a hike, jumping from a $11.65 billion valuation in 2025 to a projected $18.18 billion by 2031, according to Mordor Intelligence....

The Real Cost of Cabinet Decisions: Refinish or Replace?

Uncovering the Truth Behind Cabinet Decisions When it comes to sprucing up a kitchen, most folks overlook what's hanging on their walls already: those tired old cabinets. Now, are you looking at chucking them out the window for brand-new ones, or can a fresh coat of paint breathe new life into them? Well, that's where Melvin Jones, a painting virtuoso from Lexington,...

Aetna's 2027 Medicare Plans: Comprehensive Outlook

Unpacking Aetna's Medicare Strategy for 2027 Look, if there's one thing you should keep tabs on, it's how Aetna isn't just coasting by in the healthcare arena. These folks are pushing forward with new options for 2027 that prove they're serious about making healthcare not just accessible, but affordable across the board. Aetna, backed by CVS Health (NYSE: CVS), is making...

Venice's Climate Challenge: Rising Seas, Sinking Lands

Sea Rise Isn’t Just a Statistics Problem The ordeal of rising seas isn't just about staring at numbers in some spreadsheet, it's a real-world gut punch that's knocking at Venice's door. This city, known for its stunning architecture and winding canals, now serves as the poster child for what happens when Mother Nature and human errors leave a place on the brink of...

Ractigen's Breakthrough in DMD: RNA Activates Utrophin

Ractigen's New Fight Against Duchenne: A Personal Take When it comes to biotech advancements, I've seen enough breakthroughs to not get swayed easily. But Ractigen Therapeutics presenting their first-in-human data on RNA activation for Duchenne Muscular Dystrophy (DMD) kind of demands your attention. Folks, they're talking about a potential shift in handling this brutal...

Kal Plastics Showcases at Design-2-Part Expo

Kal Plastics Steps into the Limelight There's a buzz in the air, and it's all about Kal Plastics getting ready to strut their stuff at the Southern California Design-2-Part Show. Now, most folks probably don't spend their nights dreaming about thermoforming and pressure forming, but these guys sure make a case for it. They’ve got their eyes on impressing the crowd with...

Honeywell's Supply Line Snags Bait Class Action Risk

Stepping into the chaos of the stock market sometimes feels like opening Pandora's box—just when you think you've seen it all, something new tumbles out. This time around, it's Honeywell Aerospace (NasdaqGS: HONA) playing catch with hot coals, and a burning class-action lawsuit smolders in the air. Deadline Looms for Investors in Class Action Heads up, folks! If you've...